Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia
Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia
复制标题
DOI：
10.1093/sleep/31.4.489
复制
发表时间：
2008-04-01
期刊：
影响因子：
5.6
通讯作者：
Kalista, Tasha
中科院分区：
文献类型：
--
作者：
Manber, Rachel;Edinger, Jack D.;Kalista, Tasha
研究目的：失眠影响重度抑郁症（MDD）的病程，阻碍治疗反应，并增加抑郁症复发的风险。本研究是在抗抑郁药物艾司西酞普兰（EsCIT）的基础上，对失眠患者进行认知行为治疗（CBTI）的初步评估。设计和环境：在单一学术医疗中心进行的随机、对照、试点研究。参与者：30名重度抑郁症和失眠患者（61%为女性，平均年龄35 - 18岁）。干预措施：EsCIT和7次CBTI或CTRL（准脱敏）个体化治疗。测量和结果：在基线和治疗2、4、6、8和12周后，用HRSD17和SCID的抑郁部分进行抑郁评估，由与治疗分配不相关的评分者进行评分。主要结局是研究结束时重度抑郁症的缓解，这需要HRSD17评分
Study Objective: Insomnia impacts the course of major depressive disorder (MDD), hinders response to treatment, and increases risk for depressive relapse. This study is an initial evaluation of adding cognitive behavioral therapy for insomnia (CBTI) to the antidepressant medication escitalopram (EsCIT) in individuals with both disorders.Design and setting: A randomized, controlled, pilot study in a single academic medical center.Participants: 30 individuals (61 % female, mean age 35 18) with MDD and insomnia.Interventions: EsCIT and 7 individual therapy sessions of CBTI or CTRL (quasi-desensitization).Measurements and results: Depression was assessed with the HRSD17 and the depression portion of the SCID, administered by raters masked to treatment assignment, at baseline and after 2, 4, 6, 8, and 12 weeks of treatment. The primary outcome was remission of MDD at study exit, which required both an HRSD17 score